GlassScriptPhysician profile
Sarah Davis
NPI 1871973958
$8,737.34
in general payments reported to CMS, 2019-2025
51 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,528 · 2022: $1,933 · 2023: $1,858 · 2024: $1,629 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,276.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,527.41 | 2021-2025 | |
| Novo Nordisk INC | $697.56 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $655.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $601.83 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $455.46 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $385.72 | 2021-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.64 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.93 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $295.28 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $262.42 | 2021-2024 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $253.56 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $227.48 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $169.12 | 2021-2022 | |
| Abbott Laboratories | $168.81 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3, Proclaim |
| Ironwood Pharmaceuticals, INC | $160.76 | 2021-2023 | Linzess |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.